Ocular Therapeutix, Inc. is a biopharmaceutical company committed to improving vision in the real world through innovative therapies for retinal diseases and other eye conditions. AXPAXLI™ (axitinib intravitreal implant, known as OTX-TKI), Ocular’s product candidate for retinal disease, is based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis,
and in its product candidate PAXTRAVA™ (travoprost intracameral implant or OTX-TIC), for the treatment of open-angle glaucoma or ocular hypertension.
